EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma

Mahmoud Yousef iD, Mark W Hurd, Abdelrahman Yousef, Ethan B Ludmir iD, Ashwathy B Pillai, Jennifer Peterson, Eugene J Koay iD, Sali Albarouki, Ching-Wei Tzeng, Rebecca Snyder, Matthew H G Katz, Huamin Wang und 8 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Mahmoud Yousef und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Col. Daniel Connelly Memorial Fund, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) is poor. Secondary brain metastasis (Br-M) occurs in less than 1% of patients. Clinical characteristics and molecular alterations have not been characterized in this rare patients’ subset. Materials and methods The Foundry software platform was used to retrospectively query electronic health records for patients with Br-M secondary to PDAC from 2005 to 2023; clinical, molecular, and overall survival (OS) data were analyzed.

Results

Br-M was diagnosed in 44 patients with PDAC. Median follow-up was 78 months; median OS from initial PDAC diagnosis was 47 months. Median duration from PDAC diagnosis to Br-M detection was 24 months; median OS from Br-M diagnosis was 3 months. At Br-M diagnosis, 82% (n = 36) of patients had elevated CA19-9. Lung was the most common preexisting metastatic location (71%) with Br-M, followed by liver (66%). Br-M were most frequently observed in the frontal lobe (34%, n = 15), cerebellar region (23%, n = 10), and leptomeninges (18%, n = 8). KRAS mutations were detected in 94.1% (n = 16) of patients who had molecular data available (n = 17) with KRASG12V being the most frequent subtype 47% (n = 8); KRASG12D in 29% (n = 5); KRASG12R in 18% (n = 3). Patients who underwent Br-M surgical resection (n = 5) had median OS of 8.6 months, while median OS following stereotactic radiosurgery only (n = 11) or whole-brain radiation only (n = 20) was 3.3 and 2.8 months, respectively.

Conclusion

Br-M is a late PDAC complication, resulting in an extremely poor prognosis especially in leptomeningeal disease. KRAS was mutated in 94.1% of the patients and the KRASG12V subtype was prevalent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesPrognosisAdultAged, 80 and overProto-Oncogene Proteins p21(ras)Mutation

Stichwörter der Autor:innen

KRASPDACbrain metastasesgenetic testingmutationpancreatic cancer

Substanzen

Proto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, United States.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

ORCID-Profile: Mahmoud Yousef, Ethan B Ludmir, Eugene J Koay, Dan Zhao

Förderung

  • NCI NIH HHS
  • Col. Daniel Connelly Memorial Fund
  • National Cancer Institute

Zitieren

APA

Yousef, M., Hurd, M. W., Yousef, A., Ludmir, E. B., Pillai, A. B., Peterson, J., Koay, E. J., Albarouki, S., Tzeng, C. W., Snyder, R., Katz, M. H. G., Wang, H., Overman, M. J., Maitra, A., Pant, S., Smaglo, B. G., Wolff, R. A., Yao, J., Shen, J. P., & Zhao, D. (2025). Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae182

Vancouver

Yousef M, Hurd MW, Yousef A, Ludmir EB, Pillai AB, Peterson J, et al. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae182

BibTeX
@article{Yousef2025,
  author = {Yousef, Mahmoud and Hurd, Mark W and Yousef, Abdelrahman and Ludmir, Ethan B and Pillai, Ashwathy B and Peterson, Jennifer and Koay, Eugene J and Albarouki, Sali and Tzeng, Ching-Wei and Snyder, Rebecca and Katz, Matthew H G and Wang, Huamin and Overman, Michael J and Maitra, Anirban and Pant, Shubham and Smaglo, Brandon G and Wolff, Robert A and Yao, James and Shen, John P and Zhao, Dan},
  title = {Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae182}
}
Kostenlos starten →